Segment Reporting (Tables)

3 Months Ended

Mar. 31, 2026

The following table provides the operating financial results of the Biotechnology segment:


	Three Months Ended March 31,
	2026		2025
Total revenues	$	—	$	—
Significant segment expenses:
Research and development expense	312		808
General and administrative expense	1,291		2,217
Loss on disposal of assets	37		26
Gain on lease termination	—		(5,974)
Total operating expenses	1,640		(2,923)
Interest and dividend income	—		32
Gain on settlement of accounts payable	—		191
Change in fair value of contingent liability	(188)		(136)
Total other income	(188)		87
Segment net (loss) income	$	(1,828)	$	3,010